We analyzed the correlation between FAS mRNA expression and the sensitivity of different tumor cell lines to target drugs for NSCLC (vemurafenib, dabrafenib, crizotinib and carbozantinib), pancreatic cancer (erlotinib) and breast cancer (afatinib). The gene discussed is FAS; the disease is familial pancreatic carcinoma.